Journal of Literature Pharmacy Sciences

Parkinson Hastalığı, Genetik Faktörler ve Endoplazmik Retikulum Stresi: Sistematik Derleme
Parkinson's Disease, Genetic Factors and Endoplasmic Reticulum Stress: Systemic Review
Asunur ADALIa, Selinay Başak ERDEMLİ-KÖSEa,b, Anıl YİRÜNa,c, Pınar ERKEKOĞLUa,d
aHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Ankara, TÜRKİYE
bBurdur Mehmet Akif Ersoy Üniversitesi Fen-Edebiyat Fakültesi, Kimya Bölümü, Burdur, TÜRKİYE
cÇukurova Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Adana, TÜRKİYE
dHacettepe Üniversitesi Aşı Enstitüsü, Aşı Teknolojisi ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2021;10(3):343-57
doi: 10.5336/pharmsci.2021-83291
Article Language: TR
Full Text
ÖZET
 Parkinson hastalığı (PH), popülasyonun önemli bir kısmını etkileyen, ilerleyici özellikte, nörodejeneratif bir hastalıktır. Çok faktörlü oluşum mekanizmaları tam olarak aydınlatılamadığı için patogenezi üzerinde birçok çalışma yürütülmektedir. PH gelişiminde en önemli risk faktörünün yaş olduğu ve hastalığın insidansının yaş ile arttığı bilinmektedir. Pestisitler, herbisitler ve ağır metaller gibi çevresel kirleticilere maruziyet de PH ile ilişkilendirilmiştir. Hastalığın patogenezinde rol oynayan genler arasında Parkin (PARK2), PTEN ile indüklenen kinaz (PINK1; PARK6), PH proteini 7 (DJ-1, PARK7), α-sinüklein (PARK1/4) ve lösince zengin tekrarlı kinaz 2 (LRRK2, PARK8) sayılabilir. Endoplazmik retikulum (ER) stresi; PH, Alzheimer hastalığı, Huntington hastalığı, amyotrofik lateral skleroz ve obezite gibi birçok hastalıkla ilişkilidir ve son yıllarda üzerinde en çok çalışılan konulardan biri olmuştur. PH'de nöronal ölüm, oksidatif stres ve mitokondriyal disfonksiyonla ER stresinin, nörodejenerasyona yol açtığı gözlemlenmiştir. Çalışmalara göre oluşan ER stresinin düzeyi çok önemlidir, PH patogenezinde doğrudan hastalık oluşturma potansiyeline sahip olmamakla beraber nörodejenerasyona ortam hazırladığı ve ilerlemesini sağladığı görülmüştür. ER stresinin, in vitro/in vivo şartlarda PH modelleri üzerinde aydınlatılması ve ER stresi mekanizmalarının incelenmesinin, hastalığın tedavisinde etkili yeni nöroprotektif ajanların geliştirilmesinde büyük önemi olacaktır. Bu derlemede; PH, ER stresi, ER stres yolağında görev alan proteinler, katlanmamış protein yanıtı ve ER stresi ile PH arasındaki ilişkinin incelenmesi amaçlanmıştır.

Anahtar Kelimeler: Endoplazmik retikulum stresi; Parkinson hastalığı; nörodejenerasyon
ABSTRACT
 Parkinson's disease (PD) is a progressive neurodegenerative disease affecting a significant population. Since multi-factor formation mechanisms are not fully elucidated, many studies are being conducted on its pathogenesis. It is known that age is the most important risk factor in the development of PD and its incidence increases with age. Exposure to environmental pollutants such as pesticides, herbicides and heavy metals were also associated with PD. Among the genes involved in the pathogenesis, Parkin (PARK2), PTEN-induced kinase (PINK1; PARK6), PD protein 7 (DJ-1, PARK7), α-synuclein (PARK1/4) and leucine-rich repeat kinase 2 (LRRK2, PARK8) take place. Endoplasmic reticulum (ER) stress, a highly investigated subject in the last years, is associated with many diseases such as PD, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and obesity. It has been observed that neuronal death, oxidative stress, mitochondrial dysfunction and ER stress lead to neurodegeneration in PD. According to these studies, the level of ER stress is very important. Although it does not have potential to have a direct effect on the pathogenesis of PD, it has been observed that it prepares the environment for neurodegeneration and ensures its progression. The elucidation of ER stress on PD models and investigation of ER stress mechanisms will be of great importance in the development of new effective neuroprotective agents in treatment. In this review, we aimed to investigate and give information about PD, ER stress, proteins involved in the ER stress pathway, unfolded protein response (UPR) and the relationship between ER stress and PD.

Keywords: Endoplasmic reticulum stres; Parkinson's disease; neurodegeneration
REFERENCES:
  1. Mercado G, Valdés P, Hetz C. An ERcentric view of Parkinson's disease. Trends Mol Med. 2013;19(3):165-75. [Crossref] [PubMed] 
  2. Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci. 2018;10:109. [Crossref] [PubMed] [PMC] 
  3. DeMaagd G, Philip A. Parkinson's disease and its management: Part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T. 2015;40(8):504-32. [PubMed] [PMC] 
  4. Omura T, Kaneko M, Okuma Y, Matsubara K, Nomura Y. Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid Med Cell Longev. 2013;2013: 239854. [Crossref] [PubMed] [PMC] 
  5. Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 2013;12(1):105-18. [Crossref] [PubMed] 
  6. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. [Crossref] [PubMed] 
  7. Calì T, Ottolini D, Brini M. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. Biofactors. 2011;37(3): 228-40. [Crossref] [PubMed] 
  8. Türk Nöroloji Derneği [İnternet]. Copyright © 2020 Türk Nöroloji Derneği [Erişim tarihi: 14.9.2020]. Dünya Beyin Günü basın bülteni. Erişim linki: [Link] 
  9. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(4 Suppl 1):S19-32. [Crossref] [PubMed] 
  10. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83. [Crossref] [PubMed] 
  11. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27(9):561-8. [Crossref] [PubMed] 
  12. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20): 2674-9. [Crossref] [PubMed] 
  13. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35. [Crossref] [PubMed] 
  14. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-80. [Crossref] [PubMed] 
  15. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord. 2002;8(5):297-309. [Crossref] [PubMed] 
  16. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276 (5321):2045-7. [Crossref] [PubMed] 
  17. Heman-Ackah SM, Manzano R, Hoozemans JJM, Scheper W, Flynn R, Haerty W, et al. Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons. Hum Mol Genet. 2017;26(22):4441-50. [Crossref] [PubMed] [PMC] 
  18. Pupyshev AB, Korolenko TA, Akopyan AA, Amstislavskaya TG, Tikhonova MA. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression. Neurosci Lett. 2018;672:140-4. [Crossref] [PubMed] 
  19. Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, et al. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest. 2015;125(7):2721-35. [Crossref] [PubMed] [PMC] 
  20. Lutz AK, Exner N, Fett ME, Schlehe JS, Kloos K, Lämmermann K, et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem. 2009; 284(34):22938-51. [Crossref] [PubMed] [PMC] 
  21. Ferreira M, Massano J. An updated review of Parkinson's disease genetics and clinicopathological correlations. Acta Neurol Scand. 2017; 135(3):273-84. [Crossref] [PubMed] 
  22. Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood AJ, et al. G2019S-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons. J Neurosci. 2016;36(28):7415-27. [Crossref] [PubMed] [PMC] 
  23. Yoon JH, Mo JS, Kim MY, Ann EJ, Ahn JS, Jo EH, et al. LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. Biochim Biophys Acta Mol Cell Res. 2017; 1864(12):2356-68. [Crossref] [PubMed] 
  24. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci. 2003;24(3):159-60. [Crossref] [PubMed] 
  25. Martinat C, Shendelman S, Jonason A, Leete T, Beal MF, Yang L, et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol. 2004;2(11):e327. [Crossref] [PubMed] [PMC] 
  26. Batelli S, Invernizzi RW, Negro A, Calcagno E, Rodilossi S, Forloni G, et al. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. Neurodegener Dis. 2015; 15(1):13-23. [Crossref] [PubMed] 
  27. Ablat N, Lv D, Ren R, Xiaokaiti Y, Ma X, Zhao X, et al. Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson's disease. Molecules. 2016;21(9):1107. [Crossref] [PubMed] [PMC] 
  28. Tang FL, Erion JR, Tian Y, Liu W, Yin DM, Ye J, et al. VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson's disease. J Neurosci. 2015; 35(29):10613-28. [Crossref] [PubMed] [PMC] 
  29. Chen X, Kordich JK, Williams ET, Levine N, Cole-Strauss A, Marshall L, et al. Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A. 2019;116(12):5765-74. [Crossref] [PubMed] [PMC] 
  30. Wang W, Wang X, Fujioka H, Hoppel C, Whone AL, Caldwell MA, et al. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med. 2016;22(1):54-63. [Crossref] [PubMed] [PMC] 
  31. Kurman Y. Parkinson hastalığı ve ilişkili olduğu genler [Parkinson disease and associated genes]. Düzce Üniversitesi Bilim ve Teknoloji Dergisi. 2018;6(1):231-9. [Crossref] 
  32. Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016;80(5):766-75. [Crossref] [PubMed] [PMC] 
  33. Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science. 2017;357(6357):1255-61. [Crossref] [PubMed] [PMC] 
  34. Post MR, Lieberman OJ, Mosharov EV. Can interactions between α-synuclein, dopamine and calcium explain selective neurodegeneration in Parkinson's disease? Front Neurosci. 2018;12:161. [Crossref] [PubMed] [PMC] 
  35. Westrate LM, Lee JE, Prinz WA, Voeltz GK. Form follows function: the importance of endoplasmic reticulum shape. Annu Rev Biochem. 2015;84:791-811. [Crossref] [PubMed] 
  36. Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2016; 73(1):79-94. [Crossref] [PubMed] [PMC] 
  37. Görlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal. 2006;8(9-10):1391-418. [Crossref] [PubMed] 
  38. Köse Ö, Erkekoğlu P, Özyurt B, Koçer Gümüşel B. Endoplazmik retikulum stresi ve obezite ilişkisine genel bir bakış [An overview of the endoplasmic reticulum stress and interrelation with obesity: review]. Turkiye Klinikleri J Pharm Sci. 2017;6(2):77-93. [Crossref] 
  39. Timmins JM, Ozcan L, Seimon TA, Li G, Malagelada C, Backs J, et al. Calcium/ calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest. 2009;119(10): 2925-41. [Crossref]  [PubMed]  [PMC] 
  40. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev. 2006;86(4):1133-49. [Crossref] [PubMed] 
  41. Nishikawa S, Brodsky JL, Nakatsukasa K. Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). J Biochem. 2005;137(5):551-5. [Crossref] [PubMed] 
  42. Tatar M, Tatar T. Endoplazmik retikulum stresi ve ilişkili hastalıklar [Endoplasmic reticulum stress and related diseases]. Osmangazi Tıp Dergisi. 2019;41(3):294-303. [Link] 
  43. Naidoo N. The endoplasmic reticulum stress response and aging. Rev Neurosci. 2009; 20(1):23-37. [Crossref] [PubMed] 
  44. Sarvani C, Sireesh D, Ramkumar KM. Unraveling the role of ER stress inhibitors in the context of metabolic diseases. Pharmacol Res. 2017;119:412-21. [Crossref] [PubMed] 
  45. Tsujii S, Ishisaka M, Hara H. Modulation of endoplasmic reticulum stress in Parkinson's disease. Eur J Pharmacol. 2015;765:154-6. [Crossref] [PubMed] 
  46. Gardner RG, Swarbrick GM, Bays NW, Cronin SR, Wilhovsky S, Seelig L, et al. Endoplasmic reticulum degradation requires lumen to cytosol signaling. Transmembrane control of Hrd1p by Hrd3p. J Cell Biol. 2000;151(1):69-82. [Crossref] [PubMed] [PMC] 
  47. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900-17. [Crossref]  [PubMed]  [PMC] 
  48. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7(9): 880-5. [Crossref] [PubMed] [PMC] 
  49. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 1994;8(4):453-64. [Crossref] [PubMed] 
  50. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12(7):982-95. [Crossref]  [PubMed]  [PMC] 
  51. Credle JJ, Forcelli PA, Delannoy M, Oaks AW, Permaul E, Berry DL, et al. α-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease. Neurobiol Dis. 2015;76:112-25. [Crossref] [PubMed] 
  52. Valdés P, Mercado G, Vidal RL, Molina C, Parsons G, Court FA, et al. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci U S A. 2014;111(18):6804-9. [Crossref] [PubMed] [PMC] 
  53. Egawa N, Yamamoto K, Inoue H, Hikawa R, Nishi K, Mori K, et al. The endoplasmic reticulum stress sensor, ATF6α, protects against neurotoxin-induced dopaminergic neuronal death. J Biol Chem. 2011;286(10):7947-57. [Crossref]  [PubMed]  [PMC] 
  54. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313(5785):324-8. [Crossref] [PubMed] [PMC] 
  55. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Par kinson's disease. Biochem Biophys Res Commun. 2007;354(3):707-11. [Crossref] [PubMed] 
  56. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001;105(7):891-902. [Crossref] [PubMed] 
  57. Dukes AA, Van Laar VS, Cascio M, Hastings TG. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J Neurochem. 2008;106(1):333-46. [Crossref] [PubMed] [PMC] 
  58. Sado M, Yamasaki Y, Iwanaga T, Onaka Y, Ibuki T, Nishihara S, et al. Protective effect against Parkinson's disease-related insults through the activation of XBP1. Brain Res. 2009;1257:16-24. [Crossref] [PubMed] 
  59. Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem. 2005;95(4):974-86. [Crossref] [PubMed] [PMC] 
  60. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci. 2012;32(10):3301-5. [Crossref] [PubMed] [PMC] 
  61. Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, et al. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci. 2012; 32(10):3306-20. [Crossref] [PubMed] [PMC] 
  62. Holtz WA, O'Malley KL. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem. 2003;278(21):19367-77. [Crossref] [PubMed] 
  63. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 2006;441(7092):513-7. [Crossref] [PubMed] 
  64. Fouillet A, Levet C, Virgone A, Robin M, Dourlen P, Rieusset J, et al. ER stress inhibits neuronal death by promoting autophagy. Autophagy. 2012;8(6):915-26. [Crossref] [PubMed] [PMC] 
  65. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci. 2002;22(24):10690-8. [Crossref] [PubMed] [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com